Intervention
Nicotine patch
ClinicalTrials.gov intervention label
Clinical trials
18 shownEvaluating Smoking Cessation Interventions for PWH in South AfricaNCT05413122 · 2023-11-27
RECRUITINGEnding Tobacco Use Through Interactive Tailored Messaging for Cambodian People Living With HIV/AIDSNCT05746442 · 2023-01-11
RECRUITINGAdapting and Evaluating a Tobacco Use Cessation Program for People Living With HIV in Uganda and ZambiaNCT05487807 · 2023-09-13
UNKNOWNIntegrating Tobacco Use Cessation Into HIV Care and Treatment in Kisumu County, KenyaNCT05351606 · 2023-05-16
COMPLETEDEvoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)NCT05136690 · 2022-04-27
COMPLETEDAutomated Video-Assisted Smoking Treatment for People Living With HIVNCT05014282 · 2021-12-15
ACTIVE_NOT_RECRUITINGComparing Two Behavioral Approaches to Quitting Smoking in Mental Health SettingsNCT05030272 · 2021-09-21
COMPLETEDLearn to Quit-HIV Pilot StudyNCT04609514 · 2021-01-25
COMPLETEDOptimizing Tobacco Use Treatment for PLWHANCT04176172 · 2020-02-17
ACTIVE_NOT_RECRUITINGPersistence Targeted Smoking Cessation in Serious Mental Illness (SMI)NCT03873337 · 2019-04-22
COMPLETEDAssessing the Integration of Tobacco Cessation Treatment Into Lung Cancer Screening (LCS)NCT03611881 · 2019-04-01
COMPLETEDTreating Smokers With Mental IllnessNCT03822416 · 2019-03-01
COMPLETEDCognition and Smoking Relapse (HCS)NCT03169101 · 2016-07-01
COMPLETEDInternet-Administered Smoking Cessation Treatment for Overweight and Obese SmokersNCT01259466 · 2010-07-01
COMPLETEDNicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast CancerNCT00751101 · 2007-08-20
TERMINATEDNeural Inhibition as a Mechanism of Nicotine Dependence Among Persons With SchizophreniaNCT00407277 · 2007-02-01
COMPLETEDComputer-Assisted Counseling in Helping African American Smokers Stop SmokingNCT00310141 · 2002-04-08
COMPLETEDNicotine Patch for Nicotine Dependence in Individuals With Schizophrenia or Schizoaffective Disorder - 1NCT00046813 · 2001-08-01
TERMINATEDCommon conditions
Smoking Cessation7Schizophrenia4Tobacco Use Disorder4Nicotine Dependence3Schizoaffective Disorder3HIV2HIV/AIDS2Mental Illness2Tobacco Use2Tobacco Use Cessation2Bipolar Disorder1Bipolar Disorder I1Bipolar II Disorder1Breast Cancer1Chemotherapeutic Agent Toxicity1Cigarette Smoking1Cognitive Impairment Associated With Schizophrenia1Comorbidities and Coexisting Conditions1Lung Cancer1Major Depressive Disorder1Obesity1Overweight1Palmar-plantar Erythrodysesthesia1Persistent Depressive Disorder1Psychosis1
Leading sponsors
H. Lee Moffitt Cancer Center and Research Institute2University of California, San Francisco2Abramson Cancer Center at Penn Medicine1Centre for Addiction and Mental Health1Duke University1Johns Hopkins University1M.D. Anderson Cancer Center1Massachusetts General Hospital1Merck Sharp & Dohme LLC1National Institute on Drug Abuse (NIDA)1Rutgers, The State University of New Jersey1University of Minnesota1University of Pennsylvania1University of Southern California1Wake Forest University Health Sciences1
Trial status mix
COMPLETED11
ACTIVE_NOT_RECRUITING2
RECRUITING2
TERMINATED2
UNKNOWN1
Phase mix
NA8
PHASE23
PHASE43
PHASE12
PHASE32
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.